Wellington Management Group LLP Buys 412,399 Shares of PROCEPT BioRobotics Corporation $PRCT

Wellington Management Group LLP lifted its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 47.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,274,004 shares of the company’s stock after buying an additional 412,399 shares during the quarter. Wellington Management Group LLP owned approximately 2.22% of PROCEPT BioRobotics worth $28,767,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC increased its holdings in PROCEPT BioRobotics by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock valued at $1,101,000 after acquiring an additional 1,286 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of PROCEPT BioRobotics by 9.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock valued at $8,923,000 after purchasing an additional 13,767 shares during the last quarter. Intech Investment Management LLC grew its position in shares of PROCEPT BioRobotics by 54.4% during the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock valued at $1,654,000 after purchasing an additional 10,002 shares in the last quarter. Prudential Financial Inc. grew its position in shares of PROCEPT BioRobotics by 100.4% during the second quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock valued at $393,000 after purchasing an additional 3,415 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of PROCEPT BioRobotics by 6.9% in the second quarter. State Street Corp now owns 1,269,110 shares of the company’s stock worth $73,101,000 after purchasing an additional 81,849 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
• Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on PRCT shares. Piper Sandler decreased their target price on PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th. UBS Group downgraded PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective on the stock. in a research note on Tuesday, July 28th. TD Cowen decreased their price objective on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Jefferies Financial Group reiterated a “hold” rating and set a $20.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Finally, William Blair lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $25.09.

PROCEPT BioRobotics Stock Up 6.5%

Shares of NASDAQ:PRCT opened at $22.76 on Friday. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -11.73 and a beta of 0.91. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $41.51. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $20.35 and a 200 day moving average price of $23.69.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The company’s revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.35) earnings per share. As a group, equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, CEO Larry Wood purchased 23,900 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the acquisition, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 1,000 shares of company stock worth $28,480. Insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.